Showing 20 of 100 recruiting trials for “carcinoma-of-esophagus”
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
RecruitingNCT07266363 ↗
Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
👨⚕️ David H Wang, MD PhD, VA Ann Arbor Healthcare System, Ann Arbor, MI📍 7 sites📅 Started Oct 2024View details ↗
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
👨⚕️ zhenyu ding, MD, West China Hospital of Sichuan University, ChengDu, China📍 1 site📅 Started Oct 2024View details ↗
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma
👨⚕️ Sakti Chakrabarti, MD, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center📍 1 site📅 Started Sep 2024View details ↗
RecruitingNCT06713993 ↗
Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
👨⚕️ Marine JARY, MD, CHU Estaing de Clermont Ferrand/FRANCE📍 1 site📅 Started Sep 2024View details ↗
RecruitingNCT06550063 ↗
HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes
👨⚕️ John V Reynolds, MBBCh,MD, Trinity St James Cancer Institute📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06558786 ↗
Registry for Esophageal and Gastroesophageal Junction Cancer
👨⚕️ Daniela Molena, MD, Memorial Sloan Kettering Cancer Center📍 1 site📅 Started Aug 2024View details ↗
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Enrolling by InvitationNCT06475196 ↗
Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
Myosteatosis in Oeso-gastric Cancer: Clinical Impacts
👨⚕️ Yannick Deswysen, MD, Cliniques universitaires Saint-Luc- Université Catholique de Louvain📍 1 site📅 Started May 2024View details ↗
RecruitingNCT07050576 ↗
Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →